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Background: This study evaluated the effects of C. verbenacea essential oil topically administered in a rat
periodontitis model.
Methods: Periodontitis was induced on rats in one of the mandibular first molars assigned to receive a ligature.
Animals were randomly divided into two groups: a) non-treatment group (NT) (n = 18): animals received 1mL of
vehicle; b) C. verbenacea group (C.v.) (n = 18): animals received 5mg/Kg of essential oils isolated from C. verbenacea.
The therapies were administered topically 3 times daily for 11 days. Then, the specimens were processed for
morphometric analysis of bone loss. The ligatures were used for microbiological assessment of the presence of
Aggregatibacter actinomycetemcomitans, Tannerella forsythia and Porphyromonas gingivalis using PCR. The gingival
tissue was collected to Elisa assay of interleukin (IL)-1α and IL-10 levels.
Results: Bone loss was inhibited by C. verbenacea when compared to the NT group (p < 0.05). A decrease in the
levels of IL-1α and increase in the IL-10 amounts was observed in the C.v. group as compared to NT group
(p < 0.05). A lower frequency of P. gingivalis was found in C.v. group (p < 0.05).
Conclusion: C. verbenacea essential oil topically administered diminished alveolar bone resorption, promoting a
positive local imbalance in the pro/anti-inflammatory system and reducing the frequency of detection of P.
gingivalis.
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Periodontitis is one of the main chronic inflammatory dis-
eases presenting the most prevalent form of bone path-
ology in humans [1]. Indeed, a majority of adults suffer
from moderate periodontitis, with up to 15% of the popu-
lation being affected by severe generalized periodontitis at
some period in their lives [2]. This disease is characterized
by an infectious condition leading to the occurrence of
supporting tissue destruction, which is host-mediated by
local production of immune-inflammatory markers in re-
sponse to pathogens and their products [3]. Innumerous
pro- and anti-inflammatory mediators have been identified* Correspondence: fernanda@ribbeiro.com
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reproduction in any medium, provided the orin the gingival tissue or in crevicular fluid as a result of
cellular responses to periodontopathogens [4-6]. Among
the host mediators produced after microbial recognition,
the pro-inflammatory cytokine interleukin (IL)-1 has been
described to represent important role in periodontitis
pathogenesis, being associated with inflammatory cell
migration and osteoclastogenesis progression [7,8]. Con-
versely to the destructive mechanism that involves pro-
inflammatory cytokines, regulatory pathways mediated by
anti-inflammatory mediators such as IL-10 can protect
periodontal tissues. In fact, it has been evidenced that
IL-10(-/-) mice present increased susceptibility to P.
gingivalis-induced alveolar bone loss, suggesting a role for
IL-10 in the control of destructive inflammation [9].
Within this context, studies have investigated strategies
to modulate the host’s immune-inflammatory responseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clinical and clinical studies showed that both conventional
Nonsteroidal anti-inflammatory drugs (NSAIDs) and those
selective inhibitors of Cyclooxygenase-2 (COX-2) are able
to modulate a host’s immune-inflammatory reaction
[10-15]. However, the systemic use of these drugs is com-
monly associated with side effects, impairing patients’ com-
pliance to their consumption [16]. Although the local
utilization of NSAIDs and other anti-inflammatory agents
has been examined in some studies, many of them have
revealed unsatisfactory results in controlling inflammation
when these drugs are topically administrated [17-19].
To overcome this aspect, there is compelling evidence
that many plants or their active components used in
traditional medicine might be useful for the treatment
of inflammatory conditions [20-22]. Considering the
growing interest in plant-derived drugs, studies have fo-
cused in the use of natural products to prevent oral dis-
eases such as periodontitis [21-26]. Cordia verbenacea,
classified as C. curassavica and popularly known as
Erva Baleeira, is a perennial plant widespread in the
Atlantic Forest and distributed along the Brazilian
coastal regions. The phytochemical analysis of products
obtained from its leaves has revealed several important
constituents such as flavonoids, trans-caryophyllene, α-
humulene and others, displaying marked anti-rheum-
atic, anti-inflammatory, analgesic, and healing activities
[27,28]. The anti-inflammatory effects of C. verbenacea
or its essential oil have been successfully evidenced in
classical models of inflammation and associated with an
important protective effect on the gastric mucosa, as
well as very low toxicity [27-30]. Besides the anti-
inflammatory properties of C. verbenacea, studies have
evidenced that this medicinal plant also displays an im-
portant antimicrobial activity [31-33]. Nevertheless, to
date, no study has investigated the impact of C. verbe-
nacea in modulating host immune-inflammatory re-
sponse and in controlling putative periodontal bacteria
in the presence of periodontitis.
New evidence regarding the immune-inflammatory ac-
tion and antibacterial impact of the C. verbenacea may
provide a wider therapeutic window for subjects with
periodontitis. Thus, the aim of present study was to de-
termine the effect of C. verbenacea essential oil locally
administered in a rat periodontitis model, by evaluating
the alveolar bone loss, cytokine levels modulation, and
microbiological alterations. The hypothesis was that top-
ical use of C. verbenacea could control the pathogens
associated with periodontal destruction, and modulate
the pattern of immune-inflammatory markers in tissues
presenting periodontitis. It could prevent, in conse-
quence, the progression of periodontal disease, repre-
senting a promising new approach for the management
of periodontitis.Methods
Plant material and extraction of essential oil
Fresh leaves and stems of C. verbenacea were collected
from the Multidisciplinary Center for Chemical, Bio-
logical, and Agricultural Research (CPQBA) of Campinas
University (UNICAMP). A voucher specimen (UEC
112744) is deposited at the Biological Institute of UNI-
CAMP. The essential oil was extracted from fresh,
chopped leaves by hydro distillation for 4 h, using a
Clevenger-type apparatus. Under these conditions, the
yield of essential oil was 0.37% (considering 80% humid-
ity). Both the crude ethanol extract and volatile oil were
analyzed by GC/MS (HP 6890/mass detector HP 5975/
automatic injector 7673 Agilent Technologies, Palo, CA)
using a HP-5 fused silica capillary column (30 m × 0.25
mm × 0.25 μm/stationary phase 5% methyl silicone). He-
lium was used as the carrier gas (1.0 mL/min-1). The de-
tector was acquired by electron impact (scan mode)
using an ionization energy of 70 eV. One micro liter of
sample was injected in the split less mode. The column
was initially heated at 60°C and then heated at 3°C/min-1
to 240°C. Injector and detector temperatures were 220°C
and 250°C, respectively. The compounds were identified
by comparing their mass spectra with the system data
bank NIST-2005. A homologous series of n-hydrocarbons
C-9-C18 and C-20 was co-injected with the sample in
order to calculate the retention index and co-injection
of authentic standards to provide additional criteria for
identification. The essential oil components were there-
fore identified crossing their retention index, with com-
parison of their mass spectrums compared to those of
authentic samples.
For the quantitative determination of α-humulene,
calibration was carried out using a standard solution of
α-humulene in acetone (25–127 μg/ml) containing dibu-
tylphthalate (200 μg/ml) as the internal standard. The
correlation between the peak area ratio and the concen-
trations of the compound was linear over the range tested.
In order to determine the contents of α-humulene, oil
samples (100.00±0.1 mg) were dissolved in acetone
(10 ml) containing the internal standard (200 μg/ml) and
aliquots (1.0 μl) injected into the GC/MS. All chemical
analyses were performed in triplicate. Purity obtained was
99% to α-humulene.
Rat periodontitis model
The animal cohort was composed of 36 male Wistar rats
weighing 308±35 g at the beginning of the study,
obtained from the Butantan Institute (São Paulo, Brazil).
The rats were 90 d old and were kept in temperature-
controlled cages, exposed to a 24-h light–dark cycle of
equal time, and had free access to water and food ad
libitum (Labina, Purina1, Paulinia, SP, Brazil) in the
Bioterium of Paulista University. The experimental
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Institutional Animal Care and Use Committee (036/10
CEP/ICS/UNIP).
In order to induce experimental periodontitis, one of
the mandibular first molars of each animal was ran-
domly assigned to receive a cotton ligature (Corrente
Algodão no. 10; Coats Corrente, São Paulo, SP, Brazil) in a
cervical position being knotted submarginally. The liga-
tures were kept in position in order to allow biofilm accu-
mulation over 11 days [15,22,25]. The contralateral tooth
was left unligated to be used as a control. This procedure
was performed under general anesthesia by intramuscular
administration of ketamine hydrochloride (10 mg/kg)
(DopalenW, Agribrands Brasil Ltda., Paulínia, SP, Brazil)
and xylazine hydrochloride (10 mg/kg) (RompunW, Bayer
S.A., São Paulo, SP, Brazil).
Treatment
After ligature placement, animals were randomly
assigned to one of the following groups, according to a
computer-generated code: Non-treatment group (NT)
(n = 18) animals received topically 1 mL of vehicle and
C. verbenacea essential oil group (C.v.) (n = 18) animals
received topically 5 mg/Kg body wt. of essential oils iso-
lated from C. verbenacea. Treatments were topically
administered with a 1 mL syringe, three times daily (7 a.m.,
1 p.m., and 8 p.m.) for 11 days. The animals were ad-
equately contained by the researchers to carry out the treat-
ments without the need for anesthesia.
The animals were evaluated at each of these moments
(7 a.m., 1 p.m., and 8 p.m.) throughout the experiment
to assess possible clinical or toxicological symptoms. At
the conclusion of the experiment, the animals' weights
were monitored and compared to the baseline. The ani-
mals were euthanized by CO2 inhalation on the 12th
day of periodontitis induction. Subsequently, the mand-
ibles were excised for morphometric analysis. For micro-
biological assessment, the ligatures were removed using
a dental nipper. The buccal gingival tissue from the area
surrounding the lower first molar submitted to experi-
mental periodontitis was also collected to enzyme-linked
immunosorbent assay (ELISA).
Measurement of alveolar bone loss
After gingival dissection, the mandibles de-fleshed after
immersion in 8% sodium hypochlorite for 4 h. The spe-
cimens were washed in running water and immediately
dried with compressed air. To distinguish the cementum
enamel junction (CEJ), 1% aqueous methylene blue solu-
tion (Sigma-AldrichW, Saint Louis, MO, USA) was ap-
plied to the specimens for 1 min and then washed in
running water. Photographs were obtained with a 6.1-
megapixel digital camera (CanonW 40D, NY, USA) on a
tripod to keep the camera parallel to the ground at theminimal focal distance. The specimens were fixed in
wax with their occlusal planes parallel to the ground and
long axes perpendicular to the camera. Photographs of
the buccal aspects were made both in test and control
sides. To validate measurement conversions, a milli-
meter ruler was photographed with all specimens [34].
Alveolar bone loss was determined on the buccal surface
of the lower first molars by the distance of the CEJ from
the alveolar bone crest, measured at three equally distant
sites. The average alveolar bone height was calculated
for each tooth.
A single examiner (G.E.B.), who was not aware of the
experimental data, carried out morphometric measure-
ments of alveolar bone loss. The measurements were per-
formed after intraexaminer calibration by evaluating 10
non-study images presenting alveolar bone loss similar to
the present study. The examiner measured the linear mea-
surements of all photographs twice within 24 hours. The
intraclass correlation showed 94.8% reproducibility.
ELISA assay
The collected tissues were placed into sterile tubes con-
taining 400 μl phosphate-buffered saline (PBS) with 0.05%
Tween-20. All samples were stored at -20°C. After, the tis-
sue was weighed, then cut into small pieces (1–2 mm3)
using scissors, and solubilized in PBS to a final concentra-
tion of 100 mg tissue/ml. After extraction on a Vortex
mixer for 10 min, each sample was centrifuged at 370 g
for 5 min, and the supernatant was collected, divided into
small portions, and stored at -70°C until use. To avoid
protease activity, the entire procedure was carried out at
4°C. The levels of IL-1α and IL-10 were determined by
ELISA using commercially available kits (Quantikine;
R&D Systems Inc., MN, USA), according to the manufac-
turer’s instructions. Samples were diluted with the kits’
diluents and dilution was taken into consideration for the
calculation of the concentration of each substance. This
concentration was calculated with a standard curve,
prepared using the standard proteins in the kit. The stand-
ard curve range used for IL-1α measurement was 15.6–
1000 pg/ml and for IL-10 the range was 31.2–1000 pg/ml.
ELISAs were run in duplicate and mean values were used
to calculate concentrations of each marker.
Microbiological assessment
For detection of P. gingivalis, T. forsythia and A. actino-
mycetemcomitans, the polymerase chain reaction (PCR)
technique was applied using specific primers reported in
the literature [35].
Initially, each removed ligature was individually placed
in microtubes containing 0.01 M Tris–EDTA solution,
pH 8 (TE). The DNA was then extracted from the sub-
gingival biofilm, as previously described [36] The PCR
amplification was performed using 5uL sample added to
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deoxynucleotide triphosphate, 2 uM of each primer, and
2U of Taq polymerase enzyme (OneTaq Polymerase, New
England Biolabs, Ipswich, MA, USA). Positive and nega-
tive controls were used in each run. For reaction, the
temperature settings were: for A. actinomycetemcomitans
and T. forsythia detection, an initial denaturation step of
2 min at 95°C, followed by 36 cycles of denaturation and
extension at 95°C for 30 seconds (s), annealing at 60°C for
60 s and extension at 68°C for 60 s, and a final elongation
step at 68°C for 120 s; for P. gingivalis detection, an initial
denaturation step at 95°C for 2 min, followed by 32 cycles
of denaturation and extension at 95°C for 60 s, annealing
at 60°C for 60 s and extension at 68°C for 60 s, and a final
elongation step at 68°C for 120 s. Reactions were done
(Eppendorf Mastercycler gradient, Hamburg, Germany)
and PCR products were separated by electrophoresis in
2% agarose gels and Tris-borate-EDTA running buffer
(pH 8.0). The DNA was stained with 0.5 mg of ethidium
bromide/mL and visualized under UV illumination. Stan-
dardized photographs of the images were taken (Canon
EOS 400D, Lake Success, NY, USA) and analyzed. The
analyses were performed at the Laboratory of Research of
Paulista University by a blinded subject.
Statistical analyses
To test the null hypothesis that essential oil of C. verbe-
nacea had no influence on alveolar bone loss and on
cytokine levels, intergroup analysis was performed by
student’s t-test. In addition, the paired student’s t-test
was used for intragroup comparisons between ligated
and unligated teeth. To test the null hypothesis that
essential oil of C. verbenacea had no effect on periodon-
tal bacteria, intergroup analysis was performed using
Fisher’s exact test. The significance level established for
all analyses was 5%.
Results
The animals did not show any signs of systemic illness
throughout the study period. The rats also did not lose
weight throughout the experimental period. Indeed, the
tested therapies did not promote side effects or altera-
tions in the animals’ behavior and in their general activ-
ity related to the toxicity. Deaths were not observed.
Morphometrical results
A significant difference in the alveolar bone loss between
unligated and ligated teeth was observed for both groups
(p < 0.05), showing that the ligatures around the teeth
were able to promote bone loss. Measurements of alveo-
lar bone loss in ligated mandibular molars revealed sig-
nificantly higher bone-loss values in the NT group
compared with C.v. group (p < 0.05). Figure 1A,C illus-
trate the morphometric findings.Gingival tissue cytokine levels
Figure 1D shows the gingival tissue mediator levels of
IL-1α and IL-10 evaluated for both groups. Eleven days
after the experimental periodontitis induction, the levels
of IL-1α were lower in C.v. group when compared to
NT group (p < 0.05). Conversely, the levels of IL-10 were
higher in tissues treated with C. verbenacea essential oil
than those not treated (p < 0.05).
Microbiological outcomes
The frequency of detection of the pathogens evaluated
in the ligature of each group is presented in Figure 1E.
Figure 1F illustrates representatives reverse transcrip-
tion–PCR products of periodontal pathogens observed
in one animal of C. verbenacea essential oil group. T.
forsythia was not detected in any ligature biofilm in both
groups. In the C.v. group, A. actinomycetemcomitans
was found in 7.1% of the rats, whereas in the NT group
this pathogen was detected in 36% of the animals. How-
ever, no significant difference in the frequency of detec-
tion between groups was observed for this pathogen
(p > 0.05). Regarding P. gingivalis detection, the C.v.
group presented a statistically lower frequency of detec-
tion, 13.5%, than NT group, in which P. gingivalis was
detected in 60% of ligatures (p < 0.05).
Discussion
Although it is well established that periodontitis is an in-
fectious disease, the host immune and inflammatory re-
sponse to the microbial challenge has an essential role in
the periodontal breakdown [3]. Considering the better
understanding of the participation of host immune-
inflammatory mediators in disease progression, the use
of modulating agents as an adjunctive therapy to the
periodontal treatment has been encouraged to provide
innovative visions of the management of periodontitis
[5,21,22,37,38]. In this context, the use of C. verbenacea,
a medicinal plant with anti-inflammatory and antimicro-
bial proprieties, could represent a promising future strat-
egy in treating periodontal diseases. This study evaluated,
for the first time, the anti-inflammatory and antibacterial
impact of topically administrated C. verbenacea in pre-
venting the progression of periodontitis. In general, the
outcomes demonstrated that the use of C. verbenacea was
effective against periodontal pathogens; it also positively
modulated immune-inflammatory response, minimizing
the alveolar bone loss in ligature-induced periodontitis.
In the current investigation, morphometric analysis
demonstrated that the therapy with topical C. verbenacea
essential oil promoted an important decrease in bone loss,
whereas in the non-treated group the periodontal break-
down was higher. This protective effect displayed by C.
verbenacea treatment may be associated with modulation
of the inflammatory reaction, as previously indicated by
Figure 1 Panel illustrating data for morphometric, immune-inflammatory, and antibacterial assays. A and B) Representative photographs
illustrating the morphometric findings of C. verbenacea essential oil group (A) and non-treatment group (B). C) Means and standard error of the
mean (SEM) of alveolar bone loss (mm) for ligated and unligated teeth in both groups. Significant difference when compared to ligated teeth (*).
Significant difference when compared to NT group (†) (student t test, p < 0.05). D) Means and SEM of IL-1α and IL-10 concentration (pg/ml)
assayed by ELISA. Significant difference when compared to NT group (‡) by student t test, p < 0.05. E) Frequency (%) of detection of periodontal
pathogens in both groups. Significant difference when compared to NT group (**) by Fisher’s exact test, p < 0.05. F) Representative reverse
transcription–polymerase chain reaction products illustrating periodontal pathogens observed in one animal of the C. verbenacea essential oil
group.
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from C. verbenacea exerted important anti-inflammatory
activity in different experiments [27,29]. In line with these
data, Sértie et al. [30] demonstrated that the topical
administration of similar doses of C. verbenacea than
those used in the current investigation significantly inhib-
ited nystatin-induced edema. The marked influence of
C. verbenacea and its components in attenuating in-
flammatory disorders could be explained, at least in
part, by the downregulation of pro-inflammatory
mediators, such as TNF-α and IL-1β [27,39]. In fact,
our results demonstrated a reduction in the pro-
inflammatory IL-1α levels when the therapy with
C. verbenacea was applied. The biologic activity of
IL-1 is extremely diverse, with the focus on the acti-
vation of acute phase proteins, prostaglandins, and
other cytokines, the induction of collagen and collage-
nase synthesis, and calcium resorption in bones [7,8].
Conversely, the topical use of C. verbenacea essential
oil in this investigation promoted an elevation in the
levels of anti-inflammatory IL-10 11 days after the
therapy. Of interest, the effects mediated by IL-10 may
involve the downregulation of pro-inflammatory mar-
kers or also present a protective role in tissue destruc-
tion, regulating both matrix metalloproteinases and
receptor activator of NF-КB (RANK) systems [40,41].
Recently, it has also been suggested that IL-10 has a
direct role in bone tissue formation, since the alveolar
bone loss in the absence of IL-10 is associated with areduced expression of osteoblast and osteocyte markers,
independently of microbial, inflammatory, or bone-
resorptive pathways [42].
In addition to modulating the IL-1 and IL-10 levels,
other mechanisms could explain the anti-inflammatory
activities exerted by C. verbenacea. Fernandes et al. [39]
demonstrated that its essential oil is able to inhibit the
production of prostaglandin-E2 (PGE2) and regulate in-
flammatory proteins, such as COX-2 and inducible nitric
oxide synthase (iNOS) enzymes. Contradictorily, Passos
et al. [27] showed that the anti-inflammatory action of
C. verbenacea was not related to the decline of PGE2
levels, suggesting that the mechanism of action of this
natural plant seems to be different from that of non-
steroidal anti-inflammatories. Obviously, since the host-
defense mechanisms are sustained by an enormous
network of pro- and anti-inflammatory mediators that
may exert antagonist and/or synergic biological activ-
ities, further studies are required to better characterize
the role of C. verbenacea in the modulation of immune-
inflammatory responses when periodontitis is present.
Previous findings have also indicated that constituents
of C. verbenacea, such as the sesquiterpenes α-humulene,
that exhibit a rapid onset and good absorption following
topical administration are probably responsible for the
anti-inflammatory actions displayed by the essential oil of
this natural plant [27,31]. Accordingly, the purity of α-
humulene in the C. verbenacea essential oil used in the
present experiments was 99%, supporting the positive
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of this medicinal plant.
In association with the better knowledge of the role of
host immune response in modulating periodontal col-
lapse, investigators have focused on the advance of novel
therapeutic strategies of host-modulatory agents for the
treatment of chronic inflammatory diseases, including
periodontal disorders [5,43,44]. NSAIDs are considered
an important pharmacologic class of agents that act as
modulators of the host response, modifying the progres-
sion of periodontal disease, as evidenced by animal
studies [10,11,15]. Although some evidences are contro-
versial, clinical data have also shown that the systemic
administration of these drugs may offer supplementary
benefits in periodontal therapy when combined with scal-
ing and root planning [12-14]. However, the systemic use
of both non-selective and selective inhibitors of COX-2
are frequently linked to various side effects, including gas-
troduodenal and renal complications, impairing patient
compliance to their use, especially when continued peri-
ods of administration are required [16]. The topical ad-
ministration of these and other anti-inflammatory agents
seems also to not promote satisfactory effects in modulat-
ing host immune response [17-19].
Conversely, earlier data have demonstrated that the nat-
ural agent C. verbenacea displayed an anti-inflammatory
activity linked to a vital protective effect on the gastric mu-
cosa, and very low toxicity in acute models of experimenta-
tion in rats when systemically or topically administered
[27-31]. Moreover, it was revealed that C. verbenacea pre-
sents an imperative antiulcer effect, contributing to the
preservation of mucosal integrity [45]. It is important to
mention that previous findings demonstrated that the po-
tent anti-inflammatory activity of this medicinal plant has
an efficacy similar to that of well-established NSAIDs [30].
For that reason, the use C. verbenacea would be important
strategy to modulate periodontal disease, avoiding the ad-
verse effects attributed to other anti-inflammatory drugs,
especially we consider that their positive effects may be
achieved using local administration, as observed in this
study. Further, this therapeutic alternative would also allow
the possibility of a longer period of drug administration in
periodontal disease treatment.
In addition to these exposed advantages concerning
the topical use of C. verbenacea essential oil, evidence
demonstrating the antibacterial potential of C. verbena-
cea and its components [31-33] could greatly support
their utilization in the therapy of infectious diseases such
as periodontitis. Our microbiological data demonstrated
that this medicinal plant might positively interfere in the
decrease of putative periodontopathogens. While a trend
toward the reduction of A. actinomycetemcomitans has
been observed, a significant decline of P. gingivalis was
verified in the present microbiological assays. In linewith these findings, Hernardez et al. [46] demonstrated
the antibacterial activity of the essential oil of C. verbe-
nacea against bacteria related to gastrointestinal, respira-
tory, and dermatological disorders, both Gram-negative
and Gram-positive. On the other hand, Michielin et al.
[33] revealed that some extracts from C. verbenacea
were more effective against Gram-positive (Staphylococ-
cus aureus and Bacillus cereus) than Gram-negative bac-
teria (Escherichia coli and Pseudomonas aeruginosa). Of
interest, to our knowledge, this is the first study to in-
vestigate the antibacterial impact of topically applied C.
verbenacea in pathogens related to periodontitis, ham-
pering a more direct comparison with the outcomes
from other investigations. Although further investiga-
tions are needed to determine the exact mechanisms
involved in the antibacterial effect of C. verbenacea, the
antimicrobial activity displayed by the essential oil in
extracts of this plant can be attributed to the presence of
constituents such as aromatic compounds, which have
previously shown antimicrobial activity [33]. Neverthe-
less, additional investigations are required to establish
which constituents are accountable for their antibacterial
properties. Interestingly, T. forsythia was not found in
any ligature biofilm in both groups of the present study.
In fact, although this species is considered a recognized
periodontal pathogen associated with human subgingival
biofilm in periodontal pockets, other studies assessing
the ligature-induced biofilm in rats also did not find T.
forsythia among the bacteria population [47].
Within the limitations of this investigation, it was
demonstrated that C. verbenacea oil topical preparation
was effective in protecting alveolar bone loss in ligature-
induced periodontitis, which might be mediated, in part,
by its inhibitory effect on the periodontal pathogens
and, in part, by its modulatory role in the immune-
inflammatory response. In the current paradigm of peri-
odontal disease, periodontal pathogens are required for
disease beginning; however, the extent and severity of
periodontal destruction are dependent on the nature of
host response to the bacterial challenge. Until now, most
of the therapeutic agents suggested as adjunctive to peri-
odontal therapy targeted antibiotic or anti-inflammatory
effects. The development of novel therapeutic strategies
combining simultaneously both the host-modulatory
effect and the antibacterial activity would increase the
likelihood of successfully managing periodontitis. The at-
tractive outcomes observed in the present study, linked
with the combined anti-inflammatory and antibacterial
therapeutic actions of C. verbenacea, support the contin-
ued investigation of this plant as a potential new way to
control the deterioration of tooth-supporting tissues in
individuals suffering from periodontal disease.
It is important to highlight that the present study did
not include therapeutic groups to evaluate other anti-
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investigation was to assess the effects of C. verbenacea.
As this study was the first to analyze whether the topical
application of C. verbenacea could promote some
protective effect against periodontal destruction, only a
control group using a vehicle substance was used in com-
parison with the C. verbenacea essential oil group.
Although it may be considered a limitation of the present
trial, we believe that the absence of other comparative
groups – such as saline or another anti-inflammatory
agent group – does not invalidate the outcomes obtained
in the present investigation. Nevertheless, a comparison
with other therapies could bring additional information
concerning the real relevance of C. verbenacea in modu-
lating periodontitis, and it needs to be evaluated in future
investigations.
Recently, the Brazilian market released this plant for
the industrial production of therapeutic agents, and a
commercial preparation with C. Verbenacea is available
to treat musculo-skeletal disorders and tendinitis. Fur-
ther data are required to consider this natural agent and
its constituents as adjunctive in periodontal therapy in
clinical practice, and provide new insights for its anti-
bacterial action and its modulation of periodontal dis-
ease progression.
Conclusion
C. verbenacea oil topical preparation is effective in pro-
tecting alveolar bone loss in ligature-induced periodon-
titis, which might be mediated, in part, by its inhibitory
effect on the periodontal pathogens and, in part, by its
modulatory role in the immune-inflammatory response.
Competing interests
There is no conflict of interest to declare.
Authors’ contributions
SPP participated in the conception and design of study and helped to
induce experimental periodontitis / GEB carried out the measurement of
alveolar bone loss / RCVC carried out the ELISA assays and microbiological
assessment / FRC helped to induce experimental periodontitis and
performed the statistical analysis / MZC helped to morphometric assay,
participated in analysis and interpretation of data and in the drafted the
manuscript / MAF and GMF carried out chemical analyses related to plant
material and extraction of essential oil / FVR participated in the design of
study and in the drafted the manuscript and carried out the ELISA assays /
All authors read and approved the final manuscript.
Acknowledgements
The authors thank Professor Daclé Juliani Macrini for making the laboratory
available in order to carry out this project.
Author details
1Depto de Odontologia, Universidade Paulista – UNIP, Av. Dr. Bacelar, 1212, 4
andar, Vila Clementino, São Paulo, SP 04026-002, Brazil. 2Multidisciplinary
Center for Chemical, Biological and Agricultural Research (CPQBA), Campinas
University, Campinas, São Paulo, Brazil.
Received: 23 May 2012 Accepted: 22 August 2012
Published: 21 November 2012References
1. Tonetti MS, Claffey N, European Workshop in Periodontology group C:
Advances in the progression of periodontitis and proposal of definitions
of a periodontitis case and disease progression for use in risk factor
research. Group C consensus report of the 5th European Workshop in
Periodontology. J Clin Periodontol 2005, 32(Suppl 6):210–213.
2. Burt B: Position paper: epidemiology of periodontal diseases.
J Periodontol 2005, 76:1406–1419.
3. Kinane DF, Preshaw PM, Loos BG, Working Group 2 of Seventh European
Workshop on Periodontology: Host-response: understanding the cellular
and molecular mechanisms of host-microbial interactions-consensus of
the Seventh European Workshop on Periodontology. J Clin Periodontol
2011, 38(Suppl 11):44–48.
4. Reinhardt RA, Stoner JA, Golub LM, et al: Association of gingival crevicular
fluid biomarkers during periodontal maintenance with subsequent
progressive periodontitis. J Periodontol 2010, 8:251–259.
5. Guimarães MR, Coimbra LS, De Aquino SG, Spolidorio LC, Kirkwood KL,
Rossa C Jr: Potent anti-inflammatory effects of systemically administered
curcumin modulate periodontal disease in vivo. J Periodontal Res 2011,
46:269–279.
6. Vieira Ribeiro F, De Mendonça AC, Santos VR, Bastos MF, Figueiredo LC,
Duarte PM: Cytokines and bone-related factors in systemically healthy
patients with chronic periodontitis and patients with type 2 diabetes
and chronic periodontitis. J Periodontol 2011, 82:1187–1196.
7. Graves D: Cytokines that promote periodontal tissue destruction.
J Periodontol 2008, 79:1585S–1591S.
8. Bloemen V, Schoenmaker T, de Vries TJ, Everts V: IL-1β favors
osteoclastogenesis via supporting human periodontal ligament
fibroblasts. J Cell Biochem 2011, 112:1890–1897.
9. Sasaki H, Okamatsu Y, Kawai T, Kent R, Taubman M, Stashenko P: The
interleukin-10 knockout mouse is highly susceptible to Porphyromonas
gingivalis-induced alveolar bone loss. J Periodontal Res 2004, 432:441 –441.
10. Gurgel BC, Duarte PM, Nociti FH JR, et al: Impact of an anti-inflammatory
therapy and its withdrawal on the progression of experimental
periodontitis in rats. J Periodontol 2004, 75:1613–1618.
11. Holzhausen M, Spolidorio DM, Muscará MN, Hebling J, Spolidorio LC:
Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2,
in experimental periodontitis in rats. J Periodontal Res 2005, 40:208–211.
12. Sekino S, Ramberg P, Lindhe J: The effect of systemic administration of
ibuprofen in the experimental gingivitis model. J Clin Peridontol 2005,
32:182–187.
13. Aras H, Cağlayan F, Güncü GN, Berberoğlu A, Kilinç K: Effect of systemically
administered naproxen sodium on clinical parameters and
myeloperoxidase and elastase-like activity levels in gingival crevicular
fluid. J Periodontol 2007, 78:868–873.
14. Azoubel MC, Sarmento VA, Cangussú V, et al: Adjunctive benefits of
systemic etoricoxib in non-surgical treatment of aggressive periodontitis:
short-term evaluation. J Periodontol 2008, 79:1719–1725.
15. Queiroz-Junior CM, Pacheco CM, Maltos KL, Caliari MV, Duarte ID, Francischi
JN: Role of systemic and local administration of selective inhibitors of
cyclooxygenase 1 and 2 in an experimental model of periodontal
disease in rats. J Periodontal Res 2009, 44:153–160.
16. Fitzgerald GA, Patrono C: The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med 2001, 345:433–442.
17. Kostrica R, Rottenberg J, Kvech J, Betka J, Jablonicky J: Randomised,
double-blind comparison of efficacy and tolerability of diclofenac
mouthwash versus placebo in mucositis of oral cavity by radiotherapy.
J Clin Res 2002, 5:1–15.
18. Xu Y, Höfling K, Fimmers R, Frentzen M, Jervøe-Storm PM: Clinical and
microbiological effects of topical subgingival application of hyaluronic
acid gel adjunctive to scaling and root planing in the treatment of
chronic periodontitis. J Periodontol 2004, 75:1114–1118.
19. Agarwal S, Mathur S, Kothiwale S, Benjamin A: Efficacy and acceptability of
0.074% diclofenac-containing mouthwash after periodontal surgery: a
clinical study. Indian J Dent Res 2010, 21:408–412.
20. Calixto JB, Campos MM, Otuki MF, Santos AR: Anti-inflammatory compounds
of plant origin. Part II. modulation of pro-inflammatory cytokines,
chemokines and adhesion molecules. Planta Med 2004, 70:93–103.
21. Paterniti I, Briguglio E, Mazzon E, et al: Effects of Hypericum Perforatum, in
a rodent model of periodontitis. BMC Complement Altern Med 2010,
23(10):73.
Pimentel et al. BMC Complementary and Alternative Medicine 2012, 12:224 Page 8 of 8
http://www.biomedcentral.com/1472-6882/12/22422. Ozdemir H, Kara MI, Erciyas K, Ozer H, Ay S: Preventive effects of
thymoquinone in a rat periodontitis model: a morphometric and
histopathological study. J Periodontal Res 2012, 47:74–80.
23. Botelho MA, Rao VS, Montenegro D, et al: Effects of a herbal gel
containing carvacrol and chalcones on alveolar bone resorption in rats
on experimental periodontitis. Phytother Res 2008, 22:442–449.
24. Basri DF, Tan LS, Shafiei Z, Zin NM: In vitro antibacterial activity of galls of
Quercus infectoria Olivier against oral pathogens. Evid Based Complement
Alternat Med 2012, 2012:632796.
25. Toker H, Ozan F, Ozer H, Ozdemir H, Eren K, Yeler H: A morphometric and
histopathologic evaluation of the effects of propolis on alveolar bone
loss in experimental periodontitis in rats. J Periodontol 2008,
79:1089–1094.
26. Napimoga MH, Benatti BB, Lima FO, et al: Cannabidiol decreases bone
resorption by inhibiting RANK/RANKL expression and pro-inflammatory
cytokines during experimental periodontitis in rats. Int Immunopharmacol
2009, 9:216–222.
27. Passos GF, Fernandes ES, Da Cunha FM, et al: Anti-inflammatory and anti-
allergic properties of the essential oil and active compounds from
Cordia verbenacea. J Ethnopharmacol 2007, 110:323–333.
28. de Oliveira DM, Luchini AC, Seito LN, Gomes JC, Crespo-López ME, Di Stasi
LC: Cordia verbenacea and secretion of mast cells in different animal
species. J Ethnopharmacol 2011, 135:463–468.
29. Sertié JA, Basile AC, Panizza S, Oshiro TT, Azzolini CP, Penna SC:
Pharmacological assay of Cordia verbenacea. III: oral and topical
antiinflammatory activity and gastrotoxicity of a crude leaf extract.
J Ethnopharmacol 1991, 31:239–247.
30. Sertié JA, Woisky RG, Wiezel G, Rodrigues M: Pharmacological assay of
Cordia verbenacea V: oral and topical anti inflammatory activity,
analgesic effect and fetus toxicity of a crude leaf extract. Phytomedicine
2005, 12:338–344.
31. de Carvalho PM JR, Rodrigues RF, Sawaya AC, Marques MO, Shimizu MT:
Chemical composition and antimicrobial activity of the essential oil of
Cordiaverbenacea D.C. J Ethnopharmacol 2004, 95:297–301.
32. Meccia G, Rojas LB, Velasco J, et al: Chemical composition and
antibacterial activity of the essential oil of Cordia verbenacea from the
Venezuelan Andes. Nat Prod Commun 2009, 4:1119–1122.
33. Michielin EM, Salvador AA, Riehl CA, Smânia AJR, Smânia EF, Ferreira SR:
Chemical composition and antibacterial activity of Cordia verbenacea
extracts obtained by different methods. Bioresour Technol 2009,
100:6615–6623.
34. Fernandes MI, Gaio EJ, Oppermann RV, Rados PV, Rosing CK: Comparison of
histometric and morphometric analyses of bone height in ligature-
induced periodontitis in rats. Braz Oral Res 2007, 21:216–221.
35. Sardi JC, Duque C, Camargo GA, Hofling JF, Gonçalves RB: Periodontal
conditions and prevalence of putative periodontopathogens and
Candida spp. in insulin-dependent type 2 diabetic and non-diabetic
patients with chronic periodontitis-A pilot study. Arch Oral Biol 2011,
56:1098–1105.
36. Casarin RC, Ribeiro Edel P, Mariano FS, Nociti FH Jr, Casati MZ, Gonçalves RB:
Levels of Aggregatibacter actinomycetemcomitans, Porphyromonas
gingivalis, inflammatory cytokines and species-specific immunoglobulin
G in generalized aggressive and chronic periodontitis. J Periodontal Res
2010, 45:635–642.
37. Elkhouli AM: The efficacy of host response modulation therapy (omega-3
plus low-dose aspirin) as an adjunctive treatment of chronic
periodontitis (clinical and biochemical study). J Periodontal Res 2011,
46:261–268.
38. Kasuyama K, Tomofuji T, Ekuni D, et al: Effects of topical application of
inorganic polyphosphate on tissue remodeling in rat inflamed gingiva.
J Periodont Res 2012, 47(2):159–164.
39. Fernandes ES, Passos GF, Medeiros R, et al: Anti-inflammatory effects of
compounds alpha-humulene and (-)-trans-caryophyllene isolated from
the essential oil of Cordia verbenacea. Eur J Pharmacol 2007, 569:228–236.
40. Chou WY, Lu CN, Lee TH, et al: Electroporative interleukin-10 gene
transfer ameliorates carbon tetrachloride-induced murine liver fibrosis
by MMP and TIMP modulation. Acta Pharmacol Sin 2006, 27:469–476.
41. Claudino M, Trombone AP, Cardoso CR, et al: The broad effects of the
functional IL-10 promoter-592 polymorphism: modulation of IL-10, TIMP-
3, and OPG expression and their association with periodontal disease
outcome. J Leukoc Biol 2008, 84:1565–1573.42. Claudino M, Garlet TP, Cardoso CR, et al: Down-regulation of expression of
osteoblast and osteocyte markers in periodontal tissues associated with
the spontaneous alveolar bone loss of interleukin-10 knockout mice. Eur
J Oral Sci 2010, 118:19–28.
43. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis.
Nat Rev Immunol 2002, 2:364–371.
44. Rogers JE, Li F, Coatney DD, et al: A p38 mitogen-activated protein kinase
inhibitor arrests active alveolar bone loss in a rat periodontitis model.
J Periodontol 2007, 78:1992–1198.
45. Roldão Ede F, Witaicenis A, Seito LN, Hiruma-Lima CA, Di Stasi LC:
Evaluation of the antiulcerogenic and analgesic activities of Cordia
verbenacea DC. (Boraginaceae). J Ethnopharmacol 2008, 119:94–98.
46. Hernandez T, Canales M, Teran B, et al: Antimicrobial activity of the
essential oil and extracts of Cordia curassavica (Boraginaceae).
J Ethnopharmacol 2007, 111:137–141.
47. Duarte PM, Tezolin KR, Figueiredo LC, Feres M, Bastos MF: Microbial profile
of ligature-induced periodontitis in rats. Arch Oral Biol 2010, 55:142–147.
doi:10.1186/1472-6882-12-224
Cite this article as: Pimentel et al.: Protective effect of topical Cordia
verbenacea in a rat periodontitis model: immune-inflammatory,
antibacterial and morphometric assays. BMC Complementary and
Alternative Medicine 2012 12:224.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
